Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Neoadjuvant Therapy in Stage II–IIIB NSCLC
ChiCTR2500110056Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Major pathologic response. Started Sep 2025; status: recruiting.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500110056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110056.